{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for lactic root_Display\ Name in Display Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
M020
(2015)
Source URL:
First approved in 2015
Source:
M020
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Oxothiazolidinecarboxylic Acid (L-2-oxothiazolidine-4-carboxylic acid, OTC) was currently undergoing evaluation in a Phase II clinical trial. It is suggested that an ideal drug may be an antisense oligonucleotide that blocks the expression of glycolate oxidase, a key enzyme in hepatic oxalate synthesis.
Status:
Possibly Marketed Outside US
Source:
M020
(2015)
Source URL:
First approved in 2015
Source:
M020
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Possibly Marketed Outside US
Source:
BLA761089
(2018)
Source URL:
First approved in 2015
Source:
Ecosom by ECOSOM.Co.,Ltd.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 346
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 346
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
FORTE Magnetic S3 Oil Control Anti-Dandfuff by FORMOSA BIOMEDICAL TECHNOLOGY CORPORATION
(2024)
Source URL:
First approved in 2015
Source:
21 CFR 358B
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
TECHNESCAN
Source URL:
First approved in 2015
Source:
NDA018321
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Skeletal imaging, radionuclide—Technetium Tc 99m oxidronate is indicated as a skeletal imaging agent in adults and children to delineate areas of abnormal osteogenesis, such as those that occur with metastatic bone disease, Paget's disease, arthritic disease, osteomyelitis, and fractures. Technetium Tc 99m oxidronate injection is a radiopharmaceutical. Exact mechanism is not known. It is generally accepted that technetium Tc 99m oxidronate localizes on the surface of hydroxyapatite crystals by a process termed chemisorption, with blood flow and/or blood concentration being most important in the delivery of the agent to sites of uptake. Visualization of osseous lesions is possible since skeletal uptake of technetium Tc 99m oxidronate is altered in areas of abnormal osteogenesis. Rapidly distributed in and cleared from blood after intravenous administration, with about half the dose normally accumulating in the skeleton within 3 to 4 hours after injection. May also locate within infarcted myocardial cells or other regions of soft tissue necrosis or calcification. Minimal uptake by soft-tissue organs, except calcified cartilage, blood vessels, and kidneys. TechneScan HDP exhibits its greatest affinity for areas of altered osteogenesis and actively metabolizing bone. Some hypersensitivity reactions, as well as nausea and vomiting, have been infrequently associated with Technetium Tc 99m Oxidronate.
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2016)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2014)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Possibly Marketed Outside US
Source:
Palmitoleic Acid by Hofstädter, P.G.
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Palmitoleic acid, commonly known as omega-7, is a rare monounsatured fatty acid, which was generally reported to benefit the skin in promoting epithelialisation, and certain gynaecological problems (vaginal mycoses). Until now, sea buckthorn (Hippophae rhamnoides), a shrub widely found in Europe and Asia, and macadamia nuts have been the principal sources. Palmitoleic acid (PMA) has anti-inflammatory and antidiabetic activities. Palmitoleic acid is a gap junction uncoupler.
